These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 17183836)
21. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study. Sasor A; Wagrowska-Danilewicz M; Danilewicz M Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901 [TBL] [Abstract][Full Text] [Related]
23. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460 [TBL] [Abstract][Full Text] [Related]
24. Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. Ibrahim GK; Kerns BJ; MacDonald JA; Ibrahim SN; Kinney RB; Humphrey PA; Robertson CN J Urol; 1993 Jan; 149(1):170-3. PubMed ID: 7678041 [TBL] [Abstract][Full Text] [Related]
25. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion. Man YG; Gardner WA Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698 [TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. Hobisch A; Rogatsch H; Hittmair A; Fuchs D; Bartsch G; Klocker H; Bartsch G; Culig Z J Pathol; 2000 Jul; 191(3):239-44. PubMed ID: 10878544 [TBL] [Abstract][Full Text] [Related]
27. Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions. El Sharkawy SL; Abbas NF; Badawi MA; El Shaer MA J Clin Pathol; 2006 Nov; 59(11):1171-4. PubMed ID: 16574721 [TBL] [Abstract][Full Text] [Related]
28. [Expression and its significance of b-FGF in human benign prostatic hyperplasia and prostatic carcinoma tissues]. Wang FL; Wang H; Qin WJ; Wu GJ; Zhang G; Li KN Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Mar; 20(2):203-5. PubMed ID: 15191726 [TBL] [Abstract][Full Text] [Related]
29. Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Mohamed MA; Greif PA; Diamond J; Sharaf O; Maxwell P; Montironi R; Young RA; Hamilton PW BJU Int; 2007 Apr; 99(4):908-15. PubMed ID: 17378849 [TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate. Dema A; Tudose N Rom J Morphol Embryol; 1998; 44(1-4):93-100. PubMed ID: 15678849 [TBL] [Abstract][Full Text] [Related]
31. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance]. Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Maygarden SJ; Novotny DB; Moul JW; Bae VL; Ware JL Mod Pathol; 1994 Dec; 7(9):930-6. PubMed ID: 7892162 [TBL] [Abstract][Full Text] [Related]
33. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Matsuyama M; Hayama T; Funao K; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R Oncol Rep; 2007 Jul; 18(1):99-104. PubMed ID: 17549353 [TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor beta 1 and androgen receptors in prostate neoplasia. Cardillo MR; Petrangeli E; Salvatori L; Ravenna L; Di Silverio F Anal Quant Cytol Histol; 2000 Oct; 22(5):403-10. PubMed ID: 11064817 [TBL] [Abstract][Full Text] [Related]
35. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Bethel CR; Faith D; Li X; Guan B; Hicks JL; Lan F; Jenkins RB; Bieberich CJ; De Marzo AM Cancer Res; 2006 Nov; 66(22):10683-90. PubMed ID: 17108105 [TBL] [Abstract][Full Text] [Related]
36. The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hyperplastic, dysplastic, and carcinomatous lesions. Leav I; McNeal JE; Ziar J; Alroy J Hum Pathol; 1998 Jul; 29(7):668-75. PubMed ID: 9670822 [TBL] [Abstract][Full Text] [Related]
37. Distribution of proliferating-cell nuclear antigen and epidermal growth factor receptor in intraepithelial squamous cell lesions of human bronchus. Yoneda K Mod Pathol; 1994 May; 7(4):480-6. PubMed ID: 7915034 [TBL] [Abstract][Full Text] [Related]
38. [Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]. Yu T; Zhu SX; Zheng S; Chen SP Zhonghua Nan Ke Xue; 2007 Mar; 13(3):222-5. PubMed ID: 17393784 [TBL] [Abstract][Full Text] [Related]
39. [Premalignant and benign lesions in nodules of adenomatous hyperplasia]. Miján Ortiz JL; Fernández Rodríguez A; Fernández Ruiz PL; de la Fuente Serrano A; Nogales Fernández F; Zuluaga Gómez A Arch Esp Urol; 1996 Sep; 49(7):684-7. PubMed ID: 9020004 [TBL] [Abstract][Full Text] [Related]
40. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia. Mirtti T; Alanen K; Kallajoki M; Rinne A; Söderström KO Prostate; 2003 Mar; 54(4):290-8. PubMed ID: 12539227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]